PhaseBio Pharmaceuticals Inc (PHASQ)

[anotherboat12]

Yes for their drug rlf-100. PB-1046 is Phase Bios and they will have their own. https://phasebio.com/pipeline/

[Whalatane]

It’s the FDA approval for the Covid indication .
RLFTF has already been granted FDA fast track status and an Orphan drug designation

Therefore if their version of VIP gets approved first .... they have the market to themselves for a min of 3 yrs ... new indication exclusivity for an existing drug .... and possibly longer

Is your VIP version isn’t fast tracked then it’s unlikely to beat RLFTF in getting approved ( assuming trials succeed )

Kiwi

[anotherboat12]

The share counts of RLFTF vs PHAS are not even comparable. If PHASE has good results, this could be another NVAX. So if RLFTF is telling the truth, Phase Bio wins big too.

[anotherboat12]

What is the difference when PHAS has great results? PhaseBio is a once a week shot vs an IV drip. They are the same compounds.

[Whalatane]

RLFTF is FDA fast tracked with an Orphan status .
It’s in trials for a new indication ... Covid
That means 3 yrs marketing exclusivity at least .... for their drug if it’s approved .
Hatch - Waxman legislation
Kiwi

[anotherboat12]

Buying this for the VIP covid treatment. If RLFTF works, this works.

[vwlibra]

DSG Supports PhaseBio Pharmaceuticals with Unified Clinical Trial Software Platform for COVID-19 Trial

https://www.biospace.com/article/releases/dsg-supports-phasebio-pharmaceuticals-with-unified-clinical-trial-software-platform-for-covid-19-trial/

July 17, 2020 13:30 UTC



MALVERN, Pa.--(BUSINESS WIRE)-- DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry has successfully launched a COVID-19 study with PhaseBio Pharmaceuticals, Inc. for its potentially pivotal clinical trial evaluating PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

[vwlibra]

PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

https://www.businesswire.com/news/home/20200716006010/en/

HOD $5.658, likely to cross $7 next week (one can hope)

[vwlibra]

PHAS upgraded by Zacks from a “hold” rating to a “buy” rating

https://dakotafinancialnews.com/2020/07/15/phasebio-pharmaceuticals-nasdaqphas-upgraded-to-buy-by-zacks-investment-research.html

PhaseBio Pharmaceuticals (NASDAQ:PHAS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The brokerage presently has a $4.75 price target on the stock. Zacks Investment Research‘s target price indicates a potential upside of 0.42% from the stock’s current price.

A number of other research analysts have also weighed in on the company. Citigroup raised their price objective on PhaseBio Pharmaceuticals from $11.00 to $12.00 in a research report on Friday, May 29th. ValuEngine upgraded PhaseBio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 17th. Needham & Company LLC started coverage on PhaseBio Pharmaceuticals in a research report on Thursday, May 28th. They issued a “buy” rating and a $18.00 price target for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $4.00 price target on shares of PhaseBio Pharmaceuticals in a research report on Tuesday, May 5th. Eight research analysts have rated the stock with a buy rating, PhaseBio Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $11.35.

Several large investors have recently made changes to their positions in PHAS. Wells Fargo & Company MN raised its stake in shares of PhaseBio Pharmaceuticals by 107.0% during the first quarter. Wells Fargo & Company MN now owns 16,832 shares of the company’s stock valued at $55,000 after acquiring an additional 8,699 shares in the last quarter. UBS Group AG raised its stake in shares of PhaseBio Pharmaceuticals by 39.8% during the fourth quarter. UBS Group AG now owns 18,059 shares of the company’s stock valued at $110,000 after acquiring an additional 5,139 shares in the last quarter. Barclays PLC raised its stake in shares of PhaseBio Pharmaceuticals by 41.1% during the fourth quarter. Barclays PLC now owns 21,969 shares of the company’s stock valued at $134,000 after acquiring an additional 6,403 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of PhaseBio Pharmaceuticals by 16.1% during the first quarter. Bank of New York Mellon Corp now owns 41,251 shares of the company’s stock valued at $136,000 after acquiring an additional 5,732 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its stake in shares of PhaseBio Pharmaceuticals by 14.8% during the first quarter. Nuveen Asset Management LLC now owns 42,501 shares of the company’s stock valued at $141,000 after acquiring an additional 5,488 shares in the last quarter. Institutional investors and hedge funds own 64.29% of the company’s stock.

[vwlibra]

STIFEL NICOLAUS MAINTAINS THEIR BUY RATING ON PHASEBIO PHARMACEUTICALS (PHAS)

July 10, 2020

https://www.markets.co/stifel-nicolaus-maintains-their-buy-rating-on-phasebio-pharmaceuticals-phas/260723/?ref=tipranks


Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Phasebio Pharmaceuticals (PHAS – Research Report) today and set a price target of $11.00. The company’s shares closed last Thursday at $4.57.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.4% and a 46.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Phasebio Pharmaceuticals is a Strong Buy with an average price target of $14.75.

[vwlibra]

Bump... TR analysts have this as a "strong buy" with an upside of $18, low of $13

Surprised this isn't seeing some discussion lately.

[coolcat57]

I get the clay sign to short but it still grinds me

[ClayTrader]

* * $PHAS Video Chart 05-28-2020 * *

Link to Video - click here to watch the technical chart video

[Leebarooski]

After Hours Watch List: PHAS
MT Newswires 5:52 PM ET
PhaseBio Pharma Starts PB1046 Trial to Treat Hospitalized COVID-19 Patients - Stock Jumps 71% After-Hours...........PHAS

[ClayTrader]

* * $PHAS Video Chart 01-10-2020 * *

Link to Video - click here to watch the technical chart video

[BoilerRoom]

Runner

[BoilerRoom]

$PHAS

[ClayTrader]

* * $PHAS Video Chart 12-19-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $PHAS Video Chart 12-18-2019 * *

Link to Video - click here to watch the technical chart video

[Halks1122]

Back in at $4.02

[Halks1122]

Back in at $4.02. Anyone out there?

[ClayTrader]

* * $PHAS Video Chart 09-25-2019 * *

Link to Video - click here to watch the technical chart video

[Halks1122]

Out for a quick flip. Easy money.

[Striker77]

Im cost averaged down to 5.35 over the last couple months. Multiple analysts have set targets from $14 to $16. The drug will get approved.

[Halks1122]

Anyone out there?

[Halks1122]

Nah, didn’t fill so I increased to $5.15. Stop loss at $4.95.

[TheFinalCD]

PHAS 5.09 was lod you got filled?

[Halks1122]

Bidding $5.10

[Striker77]

Good entry price here, you can see below alot have tried to time it, but this is the turnaround IMO

[stocktrademan]

PHAS buy 13.83

yawn...



normal chart







log chart

[TheMarketWizard]

Next, CRASH to $11. PUBLIC OFFERING!!

[TheFinalCD]

just hit 15.15

PHAS

[TheMarketWizard]

THIS WILL CRASH to $16.00 or less. 570% went up since 10 days? Unrealistic.

[TheFinalCD]

PHAS 16.30

[TheFinalCD]

PHAS 15.75

[TheFinalCD]

phas 14.80 GOOD CALL

Message in reply to:

PHAS buy 10.7

[stocktrademan]

PHAS buy 10.73



normal chart







log chart